- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Crenezumab.
Displaying page 1 of 1.
EudraCT Number: 2015-003034-27 | Sponsor Protocol Number: BN29552 | Start Date*: 2016-07-13 | |||||||||||
Sponsor Name:Roche Farma, S.A en nombre de F. Hoffman-La Roche Ltd. | |||||||||||||
Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE- BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODOMAL-TO-MILD ALZHEIMER?S DISEASE | |||||||||||||
Medical condition: Alzheimer?s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended) LT (Prematurely Ended) HU (Completed) PT (Prematurely Ended) CZ (Completed) FI (Prematurely Ended) BE (Prematurely Ended) DK (Completed) AT (Prematurely Ended) SI (Prematurely Ended) PL (Prematurely Ended) DE (Prematurely Ended) BG (Completed) HR (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003288-20 | Sponsor Protocol Number: BN29553 | Start Date*: 2017-05-07 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE | |||||||||||||
Medical condition: Alzheimer’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) EE (Prematurely Ended) PT (Prematurely Ended) BE (Completed) DE (Prematurely Ended) GR (Prematurely Ended) FR (Completed) SE (Prematurely Ended) DK (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002702-12 | Sponsor Protocol Number: BN40031 | Start Date*: 2018-07-13 | |||||||||||
Sponsor Name:Roche Farma S.A.(Soc. Unipersonal)que realiza el ensayo en España y que actúa como representante F.Hodmann-La Roche LTD | |||||||||||||
Full Title: A MULTICENTER, OPEN-LABEL, LONG-TERM EXTENSION OF PHASE III STUDIES (BN29552/BN29553) OF CRENEZUMAB IN PATIENTS WITH ALZHEIMER’S DISEASE | |||||||||||||
Medical condition: Alzheimer’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) LT (Prematurely Ended) GB (Prematurely Ended) SE (Prematurely Ended) DK (Prematurely Ended) FI (Prematurely Ended) HU (Completed) FR (Completed) BE (Completed) PL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003242-33 | Sponsor Protocol Number: GN28525 | Start Date*: 2012-11-30 | |||||||||||
Sponsor Name:Genentech, Inc. | |||||||||||||
Full Title: A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY EXTENSION OF PHASE II STUDIES ABE4869g AND ABE4955g IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE | |||||||||||||
Medical condition: Mild to moderate Alzheimer’s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
